Stroke Disorder and Treatment Market Strategic Insights and key Business Influencing Factors
Heart problems and brain problems are considered among most
dangerous medical problems, and their treatments are considered to be most
expensive. Heart strokes and brain strokes can strike any moment and can be
fatal. Hence, the market offering treatment for it is always lucrative.
Globally it is increasing rapidly. The major factor that drives the growth of
this market is the increasing high blood pressure patients. Due to increasing
alcoholism and patients with diabetes, cardiovascular diseases are increasing
the growth of this disorder and the market offering its treatment.
Market Research Future (MRFR) has published a research report
about the global stroke
disorder and treatment market that estimates huge aggrandizement in this
market between 2020 and 2027. This report provides a detailed analysis of the
market structure along with a forecast for the next seven years. It analyzes
the market on the basis of various factors including porters five force
analysis, price analysis, and supply chain analysis. Providing insights about
the current market size and future prospects, this report features expert
opinions. Profiling the key players in the market, this report covers
competitive developments such as joint ventures, mergers and acquisitions, new
product developments, strategic alliances, and research and developments in the
global market.
The global stroke disorder and treatment market has been
segmented into medicines, treatment, types, and lastly region. On the basis of
medicines, this market has been segmented into anticoagulants, anti-hypertensive,
and antiplatelet. Anticoagulants, also called blood thinners, are chemical
substances that prevent or reduce coagulation of blood, prolonging the clotting
time. Apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa), enoxaparin
(Lovenox), fondaparinux (Arixtra), heparin, rivaroxaban (Xarelto), and warfarin
(Coumadin) are some examples of anticoagulants. Antiplatelet is a member of a
class of pharmaceutical drugs that decrease platelet aggregation and inhibit
thrombus formation. They are more effective in the arterial circulation
compared anticoagulants. Examples of antiplatelet include clopidogrel (Plavix),
dipyridamole/aspirin (Aggrenox), eptifibatide (Integrilin), prasugrel
(Effient), ticagrelor (Brilinta), and ticlodipine (Ticlid). Antihypertensives
are a class of drugs that are used to treat hypertension (high blood pressure).
Examples of antihypertensives include benazepril (Lotensin), captopril
(Capoten), enalapril (Vasotec), lisinopril (Zestril and Prinivil), perindopril
(Aceon), quinapril (Accupril), ramipril (Altace), and trandolapril
(Mavik).
Treatment-based segmentation of the market covers tissue
plasminogen activator (TPA) and endovascular procedures. TPA is an enzyme
involved in the breakdown of blood clots and dissolves them. The endovascular
procedure is surgery. Being innovative, it is a less invasive procedure,
popularly used for treating problems affecting the blood vessels, such as an
aneurysm, which is a swelling or “ballooning” of the blood vessel. By types,
the market has been segmented into hemorrhagic strokes and ischemic stroke. The
weakened blood vessel leakage is called a hemorrhagic stroke. Its two
categories are aneurysms and arteriovenous malformations. Ischemic strokes
occur as a result of an obstruction within a blood vessel supplying blood to
the brain.
The regional segmentation of global stroke
treatment market cover North America, Europe, and the Asia Pacific. The key
players of this market are primarily based in these continents. In other parts
of the world, the market for stroke disorder and treatment is limited due to
less advanced medical facilities, little investment in health care, lack of
awareness about stroke disorder, and poor infrastructure. In North America and
Europe, investments in research and development (R & D) and advanced
medical facilities boost this market. According to this report, the market in
North America is expected to rise and earn maximum revenue by the end of the
forecast period. Europe is the second largest market. The Asia Pacific is
expected to be the fastest growing market for stroke disorder and treatment
because some countries in this region do have advanced medical facilities.
Key Players
The key players of global stroke disorder and treatment
market include AstraZeneca {United Kingdom (UK)}, Bayer Pharma AG (Germany),
Daiichi Sankyo (Japan), Novartis AG (Switzerland), and Pfizer {United States of
America (US)}.
Latest Industry News
The US Food & Drug Administration (FDA) has approved the
use of the Trevo clot retrieval device for up to 24 hours after symptom onset
in certain patients presenting with acute ischemic stroke. The device has been
indicated as initial therapy for ischemic stroke when used in conjunction with
tissue plasminogen activator (TPA). Earlier, the use of this device was
approved for use within 6 hours of symptom onset. 15 FEB 2018
BrainQ, an Israel-based startup aims to help stroke victims
and those with spinal cord injuries treat their injuries. Their plan to achieve
their goal is by offering personalized electromagnetic treatment protocol. They
have raised the US $ 5.3 mn for the same. The general idea behind BrainQ is to
use the patient’s brainwaves to generate a tailored treatment protocol. 15 MAY
2018.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Comments
Post a Comment